Rocket Lab (RKLB) shares surged nearly 5% to $73.92 on October 2 amid a record 20-mission Electron launch contract with Synspective that lifted the company’s backlog above 100 missions and Citi’s initiation of coverage with a Buy rating and $105 price target. The deal, the largest commercial Electron agreement to date, builds on Q2 2026 results showing $234 million revenue (up 62% year-over-year) and a $2.36 billion backlog, while ARK Invest added shares. Analyst consensus remains Buy with an average 12-month target near $109. Key near-term catalysts include the November 9 earnings release and progress toward the Neutron rocket debut, though elevated volatility and the stock’s distance from its $151 52-week high underscore execution and market sentiment risks for October price levels.